Abstract The inflamed synovial tissue of rheumatoid arthritis (RA) is characterized by an infiltration with Th1 cells that predominantly express the chemokine receptors CXCR3 and CCR5. In this study, we investigated the production of the CXCR3-agonistic chemokines CXCL9, CXCL10, and CXCL11 by synovial tissue cells and synovial fibroblast-cell lines (fourth or fifth passage) from RA patients. Concentrations of all CXCR3 ligands in synovial fluids were markedly higher in RA patients than in osteoarthritis (OA) patients. Synovial tissue cells from RA patients more strongly expressed mRNAs for CXCR3 ligands and spontaneously secreted larger amounts of these chemokine proteins than the cells from OA patients. The mRNA expression of all CXCR3 ligands was induced in synovial fibroblasts from RA patients after stimulation with interferon gamma (IFN-c), tumor necrosis factor alpha (TNF-a), or interleukin-1 beta (IL-1b). However, synovial fibroblasts significantly secreted CXCL9 and CXCL10 proteins, but not CXCL11 protein, after IFN-c stimulation and secreted only CXCL10 protein after TNF-a or IL-1b stimulation. When stimulated with a combination of IFN-c and TNF-a, these cells were able to secrete large amounts of all three chemokines. These results indicate that synovial fibroblasts may be involved in perpetuating the Th1 immune response by producing the Th1-associated CXCR3 ligands, and the synergistic effect of IFN-c and TNF-a may be important for their chemokine production in RA joints.
Introduction
The inflamed synovial tissue of rheumatoid arthritis (RA) is characterized by massive infiltration of lymphocytes and macrophages, together with an expansion of fibroblast-like synoviocytes. Cytokines are important mediators of both inflammation and joint destruction, as has been proven by the clinical efficacy of cytokine blockade in patients with active disease [1, 2] . Proinflammatory cytokines such as tumor necrosis factor alpha (TNF-a), interleukin-1 (IL-1), and IL-6 are produced mainly by tissue macrophages and synovial fibroblasts and directly involved in various aspects of the disease process. On the other hand, the expression of cytokines by T cells is relatively limited in joints. However, interferon gamma (IFN-c) and IL-17 are detectable, and these cytokines can activate the function of macrophages, synovial fibroblasts, and osteoclasts [3] , which suggests the contribution of T cells to the pathogenesis, even in established disease.
T cell infiltrates in the RA synovial tissue are primarily memory CD4+ cells with a Th1 bias, based on their ability to produce predominantly IFN-c but not IL-4 [4] . The local cytokine environment, particularly the presence of IL-12 and IL-18, is thought to favor the generation of Th1 cell activation [5, 6] . In addition, the selective recruitment of Th1 cells has recently been implicated in the Th1 predominance; the chemokine receptors CXCR3 and CCR5, known to be preferentially expressed on Th1 cells, were expressed in a majority of synovial tissue T cells [7, 8, 9] .
The expression of chemokines and their receptors plays a critical role in regulating cell traffic and positioning in inflammatory conditions. The agonistic ligands for CXCR3 include CXCL9 (monokine induced by IFN-c, or Mig), CXCL10 (IFN-c-inducible protein of 10 kDa, or IP-10), and CXCL11 (IFNinducible T-cell a chemoattractant, or I-TAC). Human genes of CXCL9-11 are located at chromosome 4q21.21, and they are $30% homogenous at an amino acid level [10] . These chemokines are induced from many cell types, such as monocytes/macrophages and endothelial cells, in response to interferon stimulation. Their major role is to induce the chemotaxis of activated T cells and natural killer cells through CXCR3 [11] . Of interest, recent evidence suggests that CXCR3 and their ligands are involved in the selective recruitment of Th1 effector cells into sites of tissue inflammation [12, 13, 14] . This notion has been supported by the observations that CXCR3 and CXCR3 ligands are expressed in several Th1-type human inflammatory diseases such as tuberculosis [15] , multiple sclerosis [16] , and sarcoidosis [17] . All three CXCR3 ligands were recently detected at high levels in the joints of RA [18, 19] .
We have previously shown that activated synovial fibroblast-cell lines from RA patients produce the cytokines with IL-2-like activity such as IL-7 and IL-15 [20] , indicating their involvement in T cell-mediated immune responses. In addition, synovial fibroblasts were identified as producers of CCR5 ligands such as macrophage inflammatory protein (MIP)-1a (CCL3), MIP1b (CCL4), and RANTES (CCL5) [21, 22] . In this study, we investigated the ability of synovial fibroblasts to produce CXCL9, CXCL10, and CXCL11, as well as the expression of these chemokines in RA synovial tissues.
Materials and methods

Patients and samples
Study patients with RA were diagnosed according to the revised criteria of the American College of Rheumatology (formally the American Rheumatism Association) [23] . All patients gave informed consent. Paired samples of serum and synovial fluid were obtained from 20 patients with RA (17 women and three men, mean age 58.5±12.3 years) and 20 patients with osteoarthritis (OA) (13 women and seven men, 71.5±8.5 years). The disease duration of RA patients was 8.5±6.7 years. Their serum Creactive protein (CRP) levels were 56±47 mg/L (normal <3 mg/ L), and 17 patients were positive for IgM rheumatoid factor (RF) (RF titer 173±190 U/ml; normal <16 U/ml). They were receiving nonsteroidal anti-inflammatory drugs (NSAIDs), <5 mg/day of prednisolone (in 18 patients), and various diseasemodifying antirheumatic drugs (DMARDs) (methotrexate in 11 patients, sulfasalazine in four, bucillamine in three, and gold salts in one).
Synovial tissue samples were obtained at the time of total joint replacement surgery from ten patients with RA (eight women and two men aged 64.7±9.9 years) and five patients with OA (three women and two men, 74.0±5.4 years). Disease duration of the RA patients was 24.1±7.7 years. Their serum CRP levels were 19±12 mg/L, and nine patients were positive for RF (RF titer 228±341 U/ml). They were receiving NSAIDs <5 mg/day of prednisolone (in eight patients), and DMARDs (methotrexate in four patients and bucillamine in two).
Isolation and culture of synovial tissue cells and synovial fibroblast cell lines Fresh synovial tissues were minced with scissors and digested for 1 h with collagenase (Wako, Osaka, Japan) and DNase (Sigma, St. Louis, Mo., USA) in RPMI-1640 (Life Technologies, Gaithersburg, Md., USA) at 37°C. After removing tissue debris through a cell strainer, the cells were washed twice with medium. The resultant single cell suspensions were dispensed into the wells of a 24-well microtiter plate (Costar, Cambridge, Mass., USA) at a density of 2·10 6 /ml in 2 ml of Dulbecco's modified Eagle's medium (DMEM) (Life Technologies) supplemented with 10% heat-inactivated fetal calf serum (FCS) (Life Technologies), 25 mM of HEPES (Life Technologies), 100 IU/ml of penicillin, and 100 lg/ ml of streptomycin. The plates were incubated at 37°C in a humidified atmosphere containing 5% CO 2 . Culture supernatants were harvested 72 h later and stored at À30°C until chemokine assay. For the detection of chemokine mRNA expression, total RNA was immediately isolated from fresh synovial tissue cells.
Synovial fibroblasts were obtained by allowing synovial tissue cells to adhere to tissue culture plates, followed by removal of nonadherent cells, as described previously [24] . These cells were split weekly, once primary cultures had reached confluence, and experiments were performed using synovial fibroblast cell lines after the third or fourth passage. The resultant cells were morphologically homogeneous fibroblast-like cells that had typical bipolar configuration under inverse microscopy, and there were <2% of contaminating lymphocytes or macrophages, as assessed by flow cytometry and staining with antibodies (Abs) against CD3, CD14, and CD19 (Beckton Dickinson, Franklin Lakes, N.J., USA), as previously described [15] . Synovial fibroblasts were incubated at a density of 1·10 5 /ml in 2 ml of DMEM with 10% FCS and allowed to adhere overnight in a 24-well microtiter plate. The medium was replaced with DMEM containing 1% FCS with or without indicated concentrations of recombinant human IFN-c (rhIFN-c) (PeproTech, London, UK), rhIL-1b (Otsuka, Tokushima, Japan), rhTNF-a (Dainippon, Osaka, Japan), rhIL-17 (R and D, Minneapolis, Minn., USA), or rhIFN-c plus rhIL-1b, rhTNF-a, or rhIL-17. Culture supernatants were harvested 48 h later and stored at À30°C until chemokine assay. Total RNA was isolated from synovial fibroblasts collected after 18 h of culture.
Immunoassays for CXCL9, CXCL10, and CXCL11
The concentrations of CXCL9 and CXCL10 were measured in duplicate by quantitative sandwich enzyme-linked immunosorbent assay (ELISA) using chemokine-specific capture and detection Abs and recombinant proteins (all from R & D) according to the manufacturer's protocol. CXCL11 was measured with a commercially available ELISA kit (R & D). The detection limit for these chemokines was 15 pg/ml.
Isolation of mRNA and reverse transcriptase-polymerase chain reaction
Total cellular RNA was extracted from fresh synovial tissue cells and cultured synovial fibroblasts using an RNA isolation kit (RNeasy Midi kit) (Qiagen, Valencia, Calif., USA) according to the manufacturer's instructions. The mRNA expression of CXCL9, CXCL10, and CXCL11 was detected by reverse transcriptasepolymerase chain reaction (RT-PCR) as described previously [25] . Briefly, complementary DNA (cDNA) was synthesized from total RNA with Molony murine leukemia virus reverse transcriptase (US Biochemical, Cleveland, O., USA) and oligo-(dT)15 primers (Promega, Madison, Wis., USA). Samples of cDNA were PCR-amplified at 30 cycles for b-actin and chemokines with rTaq DNA polymerase (Sigma) and specific primers in a thermal cycler (icyclerTM) (Bio-Rad, Hercules, Calif., USA). Each cycle consisted of 30 s of denaturation at 95°C and 30 s of annealing/extension at 60°C. Polymerase chain reaction products were electrophoresed on 1.0% agarose gel and visualized by ethidium bromide staining. The sequences of oligonucleotide primers were as follows: b-actin 5'primer-GTGGGGCGCCCCAGGCACCA, 3'primer-CTCCTT-AATGTCACGCACGATTTC; CXCL9 5'primer-TTCCTCTTG-GGCATCATCTTGCTG, 3'primer-TTGGCTGACCTGACCTG-TTTCTCCCACTT; CXCL10 5'primer-GGAACCTCCAGTCT-CAGCACC, 3'primer-GCTCCCCTCTGGTTTTAAGGAGAT; and CXCL11 5' primer-GCTATAGCCTTGGCTGTGATAT, 3'primer-GCTGGACTCCTTTGGGCAGTGGAA.
Statistical analysis
Samples with values below the detection limit for the assay were regarded as negative and assigned a value of 0, and data were expressed as means±SEM of the number of samples evaluated. The statistical significance of differences between two groups was determined by Mann-Whitney U test or Wilcoxon's signed rank test. Correlation coefficients were analyzed by Spearman's rank correlation. P values lower than 0.05 were considered significant.
Results
High concentrations of CXCL9, CXCL10, and CXCL11 in synovial fluid from rheumatoid arthritis patients Serum and synovial fluid samples were simultaneously collected from 20 RA and OA patients, respectively, and the concentrations of CXCL9, CXCL10, and CXCL11 proteins were measured by specific ELISA (Fig. 1) . The levels of all these chemokines in synovial fluid were markedly higher in RA patients than in OA patients (CXCL9 552±125 pg/ml vs 71±26 pg/ml, CXCL10 336±35 pg/ml vs 133±27 pg/ml, and CXCL11 133±34 pg/ml vs 7±4 pg/ml, respectively). In RA patients, synovial fluid levels of chemokines were all higher than serum levels (CXCL9 119±26 pg/ml, CXCL10 115±18 pg/ml, and CXCL11 115±29 pg/ml), and the differences were significant for CXCL9 and CXCL10 (P<0.005). We compared these results with clinical findings such as serum levels of CRP and RF, medication, and disease duration. However, no clear correlations were found. Serum concentrations of these chemokines were mostly undetectable or very low in OA patients (data not shown). High levels of synovial fluid CXCL9, CXCL10, and CXCL11 with a clear gradient from serum levels in RA patients indicate that CXCR3 ligands are all produced mainly in the inflamed joints.
Spontaneous production of CXCL9, CXCL10, and CXCL11 by synovial tissue cells from rheumatoid arthritis patients
The mRNA expression of CXCL9, CXCL10, and CXCL11 in synovial tissues from four RA patients and three OA patients was examined by RT-PCR (Fig. 2) . Synovial tissues of RA expressed mRNAs for these chemokines more strongly than OA tissues.
Freshly isolated synovial tissue cells from ten RA patients and five OA patients were cultured for 72 h without any simulation, and culture supernatants were measured for CXCL9, CXCL10, and CXCL11 by ELISA (Fig. 3) . Rheumatoid arthritic synovial tissues were found to secrete spontaneously large amounts of CXCL9 (1431±191 pg/ml) and CXCL10 (619±135 pg/ ml) and small amounts of CXCL11 (27±5 pg/ml). The levels of these chemokines produced from RA synovial tissues were significantly greater than from OA tissues (CXCL9 302±117 pg/ml, CXCL10 97±47 pg/ml, and CXCL11 7±4 pg/ml). It is thus likely that CXCR3 ligands are constitutively induced during joint inflammation in RA. Transcripts for all CXCR3 ligands were not significantly detected in synovial fibroblast cell lines established from RA patients (fourth or fifth passage) by RT-PCR. Cytokines such as IFN-c, TNF-a, and IL-1 are known to activate synovial fibroblasts potently to produce a number of cytokines [20, 24] . Therefore, synovial fibroblasts from three RA patients were stimulated for 18 h with IFN-c, TNF-a, IL-1b, or IL-17 alone, and the mRNA induction of CXCL9, CXCL10, and CXCL11 were determined by RT-PCR (Fig. 4) . The results show that transcripts for all CXCR3 ligands were significantly induced when cells were stimulated with IFN-c, TNF-a, and IL-1b, while IL-17 was not sufficient even at 10 ng/ ml for transcriptional activation of these chemokines (data not shown).
Production of CXCL9, CXCL10, and CXCL11 proteins by synovial fibroblasts from rheumatoid arthritis patients Synovial fibroblasts from three RA patients were stimulated for 48 h with IFN-c, TNF-a, IL-1b, or IL-17, and culture supernatants were measured for CXCL9, CXCL10, and CXCL11 proteins by ELISA (Fig. 5) . Synovial fibroblasts secreted CXCL9 and CXCL10 proteins after IFN-c stimulation (significantly at 10 ng/ ml) (337±215 pg/ml and 258±131 pg/ml, respectively) and secreted only CXCL10 protein after TNF-a or IL1b stimulation (655±332 pg/ml and 167±62 pg/ml at 10 ng/ml of TNF-a and IL-1b, respectively). Interleukin- 5 /ml in DMEM with 1% FCS) were cultured for 18 h with or without IFN-c (0.1 ng/ml and 1 ng/ml), TNF-a (1 ng/ml), or IL-1b (1 ng/ml). Expression of these chemokine mRNAs was detected by RT-PCR. Shown are the representative data from individual experiments with cell lines from three RA patients Fig. 5 Induction of CXCL9 and CXCL10 proteins in synovial fibroblasts from RA patients. Synovial fibroblast cell lines from three different patients (1·10 5 /ml in DMEM with 1% FCS) were cultured for 48 h with or without diluted concentrations (0.1 ng/ ml, 1 ng/ml, and 10 ng/ml) of IFN-c, TNF-a, IL-1b, or IL-17. Concentrations of these chemokines were measured by ELISA. Values are means±SEM 17 had no effect on chemokine secretion. Of interest, TNF-a was the most powerful inducer of CXCL10 protein: this cytokine was effective even at 0.1 ng/ml. However, CXCL11 protein was not secreted when cells were stimulated with any of these cytokines (data not shown).
We next examined the combined effect of IFN-c plus TNF-a, IL-1b, or IL-17 on the secretion of CXCR3 ligands from synovial fibroblasts (Fig. 6) . Both TNF-a and IL-1b markedly augmented the levels of IFN-c-induced chemokine secretion. Tumor necrosis factor alpha appears to be the most synergistic, because costimulation of cells with IFN-c and TNF-a induced the highest production of CXCL9 (485±163 pg/ml), CXCL10 (1830±450 pg/ml), and CXCL11 proteins (382±147 pg/ml). The effect of IL-17 was extremely limited. These results suggest that the synergistic effect of IFN-c and TNF-a may be important for the production of CXCR3 ligands by synovial fibroblasts in RA joints.
Discussion
The inflamed synovial tissue of RA is characterized by an infiltration of inflammatory cells, mainly CD4+ T cells that preferentially express the chemokine receptors CXCR3 and CCR5 [7, 8, 9] . The interaction of these receptors and their ligands may be critical in perpetuating the local Th1 immune response. In the present study, we demonstrated that CXCR3-agonistic chemokines, such as CXCL9, CXCL10, CXCL11, are all produced locally at high levels in the synovial tissue of RA, and synovial fibroblast cell lines derived from RA patients are able to secrete significant amounts of these chemokine proteins when stimulated with a combination of the Th1 cytokine IFN-c and the essential proinflammatory cytokine TNF-a. Therefore, synovial fibroblasts appear to be an important cellular source of these Th1-associated chemokines in RA joints.
CXCR3 is selectively expressed on activated T cells but not in resting T cells or other leukocyte subpopulations, while CCR5 is expressed on both T cells and monocytes [10] . Recent evidence suggests that CXCR3 and their ligands are involved in the selective recruitment of Th1 effector cells into sites of tissue inflammation [12, 13, 14] . This notion has been supported by the increased expression of CXCR3 and/or CXCR3 ligands within lesions of several Th1-type human inflammatory diseases such as tuberculosis [15] , multiple sclerosis [16] , and sarcoidosis [17] . We confirmed previous observations that the CXCR3-specific ligands CXCL9, CXCL10, and CXCL11 are all present at significantly higher levels in synovial fluid from RA patients than from OA patients [18, 19] . Thus, large amounts of these chemokines are produced during joint inflammation in RA. In addition, the clear concentration gradient of all CXCR3 agonists between the serum and synovial fluid in RA patients suggests that these chemokines may cooperatively contribute to the recruitment of T cells, particularly Th1-type cells [7] .
The mRNA expression of the three CXCR3 ligands in synovial tissue was higher in RA patients than in OA. Corresponding with this transcriptional activation, isolated synovial tissue cells from RA patients spontaneously produced large amounts of these chemokine proteins. CXCR3 ligands were originally identified as IFN-c-inducible genes mostly in monocytes and cells of macrophage lineage [26, 27, 28] . Immunohistochemical analysis of human atherosclerotic plaques has demonstrated that CD68+ macrophages highly express all three chemokines within the lesion, where IFN-cexpressing CD4+ T cells are present [29] . In the synovial tissue of active RA, highly-activated CD68+ macrophages predominate [1] . Therefore, CXCR3 ligands, like other proinflammatory cytokines and chemokines, may be the product of synovial macrophages.
CXCL10 was first identified as a synovial fibroblastderived CXCR3 ligand [30] . We showed that synovial fibroblast cell lines from RA patients, at early passage (fourth and fifth passage), were able to produce all three CXCR3 ligands in response to cytokine stimulation, e.g., a combination of IFN-c and TNF-a. This finding suggests that activated synovial fibroblasts may be another cellular source of CXCR3 ligands in RA. Previous studies have indicated that this phenotype plays an important role in the synovial infiltration of inflammatory cells such as monocytes/macrophages, lymphocytes, and neutrophils by elaborating a number of chemokines, most notably IL-8 (CXCL8), MIP-1a (CCL3), MIP-1b (CCL4), RANTES (CCL5), and stroma-derived factor 1 (CXCL12) [21, 22, 31] . The production of the CCR5-agonistic ligands MIP-1a, MIP-1b, and RANTES [10, Fig. 6 The effect of IFN-c and proinflammatory cytokines on CXCL9, CXCL10, and CXCL11 production by synovial fibroblasts from RA patients. Synovial fibroblast cell lines from three different patients (1·10 5 /ml in DMEM with 1% FCS) were incubated for 48 h with IFN-c (0.1 ng/ml) with or without TNFa (1 ng/ml), IL-1b (1 ng/ml), or IL-17 (10 ng/ml). Concentrations of these chemokines were measured by ELISA. Values are expressed as means±SEM 11], together with CXCR3 ligands, indicates that synovial fibroblasts may be involved in the localization and intensification of a Th1-type immune response into the joint.
Synovial fibroblasts are expanded and become functionally activated in the inflammatory environment of RA, as evidenced by high-level expression of class II major histocompatibility complex on primary culture cells of this lineage [32] . Cytokines may play a major role in the sustained activation of synovial fibroblasts within RA joints, because the production of cytokines such as IL-6 and TNF-a was diminished in repeated-passage cells after removal from the synovial tissue, in which numerous cytokines are abundant [33] . Interferon gamma, TNF-a, and IL-1 were found to induce transcriptional activation of all CXCR3 ligand genes in synovial fibroblast cell lines. Although these chemokines were originally identified as IFN-c-inducible genes [26, 27, 28] , CXCL10 mRNA was previously detected in TNF-a and IL-1-stimulated synovial fibroblasts [30] , in agreement with our observation. Biological activities induced by IFN-c are mediated through activation of the transcription factor signal transducers and activators of transcription 1 (STAT1) [34] , while proinflammatory activities of both TNF-a and IL-1 are primarily dependent upon activation of nuclear factor jB (NF-jB) [35] . Since conserved regulatory motifs in the upstream regions of the CXCL10 gene contain binding sites for STAT1 and NF-jB, namely the IFN stimulus response element and the NF-jB site, respectively [36] , both transcription factors may have a critical role in the gene activation of CXCR3 ligands.
Despite the induction of transcripts for CXCR3 ligands, synovial fibroblasts from RA patients secreted CXCL9 and CXCL10 proteins but not CXCL11 protein after IFN-c stimulation, and they secreted only CXCL10 protein after TNF-a and IL-1 stimulation. Therefore, the protein secretion of CXCR3 ligands in these cells appears to be differentially regulated by IFN-c, TNF-a, and IL-1, presumably at the post-transcriptional and post-translational levels. However, synovial fibroblasts were able to produce significantly all CXCR3 ligand proteins when stimulated with a combination of IFN-c and TNF-a.
In RA joints, high levels of TNF-a are produced mainly by activated macrophages. This essential proinflammatory cytokine is directly involved in the inflammatory process and, more importantly, can powerfully induce the synthesis of other inflammatory molecules in various cell types, including macrophages themselves, synovial fibroblasts, and endothelial cells [1] . However, IFN-c expression by T cells was relatively limited. Thus, synovial fibroblast production of CXCR3 ligands in RA joints may be induced by the synergism between Th1 cell-and macrophage-derived cytokines, i.e., IFN-c and TNF-a.
In conclusion, synovial fibroblasts from RA patients are able to produce all agonistic ligands for CXCR3 in response to the Th1 cytokine IFN-c and the proinflammatory cytokine TNF-a. Therefore, synovial fibroblasts are thought to contribute to the selective accumulation of Th1 cells in RA joints by producing Th1 cell-specific chemokines, CXCR3 and CCR5 ligands.
